Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A2A adenosine receptor deletion is protective in a mouse model of Tauopathy

Open access
Laurent, C, Burnouf, S, Ferry, B, Batalha, V L, Coelho, J E, Baqi, Y, Malik, E, Mariciniak, E, Parrot, S, Van der Jeugd, A, Faivre, E, Flaten, V, Ledent, C, D'Hooge, R, Sergeant, N, Hamdane, M, Humez, S, Müller, C E, Lopes, L V, Buée, L, Blum, D·2016·Molecular Psychiatry

Abstract

Consumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer's disease (AD) in humans and mitigates both amyloid and Tau burden in transgenic mouse models. However, the impact of selective A2AR blockade on the progressive development of AD-related lesions and associated memory impairments has not been investigated. In the present study, we removed the gene encoding A2AR from THY-Tau22 mice and analysed the subsequent effects on both pathological (Tau phosphorylation and aggregation, neuro-inflammation) and functional impairments (spatial learning and memory, hippocampal plasticity, neurotransmitter profile). We found that deleting A2ARs protect from Tau pathology-induced deficits in terms of spatial memory and hippocampal long-term depression. These effects were concomitant with a normalization of the hippocampal glutamate/gamma-amino butyric acid ratio, together with a global reduction in neuro-inflammatory markers and a decrease in Tau hyperphosphorylation. Additionally, oral therapy using a specific A2AR antagonist (MSX-3) significantly improved memory and reduced Tau hyperphosphorylation in THY-Tau22 mice. By showing that A2AR genetic or pharmacological blockade improves the pathological phenotype in a Tau transgenic mouse model, the present data highlight A2A receptors as important molecular targets to consider against AD and Tauopathies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mp.2014.151

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 58

  1. Flaten V, Laurent C, Coelho J, Sandau U, Batalha VL, Burnouf S et al. From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? Biochem Soc Trans 2014; 42: 587–592. · DOI
  2. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 2006; 142: 941–952. · DOI · Paper page
  3. Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S et al. Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiol Aging 2014; 35: 2079–2090. · DOI · Paper page
  4. Muller CE, Jacobson KA . Xanthines as adenosine receptor antagonists. Handbook of Experimental Pharmacology, 2011, pp 151–199. · DOI
  5. Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN . Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol 2003; 2: 366–374. · DOI
  6. Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP . Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Progr Neurobiol 2007; 81: 331–348. · DOI
  7. Sebastiao AM, Ribeiro FF, Ribeiro JA . From A1 to A3 en passant through A(2A) receptors in the hippocampus: pharmacological implications. CNS Neurol Disorders Drug Targets 2012; 11: 652–663. · doi:10.2174/187152712803581074
  8. Wei CJ, Li W, Chen JF . Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim Biophys Acta 2011; 1808: 1358–1379. · DOI
  9. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21: RC143. · DOI · Paper page
  10. Kachroo A, Schwarzschild MA . Adenosine A2A receptor gene disruption protects in an alpha-synuclein model of Parkinson's disease. Ann Neurol 2012; 71: 278–282. · DOI
  11. Canas PM, Porciuncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 2009; 29: 14741–14751. · DOI · Paper page
  12. Duyckaerts C, Bennecib M, Grignon Y, Uchihara T, He Y, Piette F et al. Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 1997; 18: 267–273. · DOI · Paper page
  13. Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, Crystal H et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging 1999; 20: 573–579. · DOI · Paper page
  14. Burnouf S, Belarbi K, Troquier L, Derisbourg M, Demeyer D, Leboucher A et al. Hippocampal BDNF expression in a tau transgenic mouse model. Curr Alzheimer Res 2012; 9: 406–410. · DOI
  15. Van der Jeugd A, Vermaercke B, Derisbourg M, Lo AC, Hamdane M, Blum D et al. Progressive age-related cognitive decline in tau mice. J Alzheimer's Dis 2013; 37: 777–788. · DOI
  16. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997; 388: 674–678. · DOI · Paper page
  17. Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A et al. NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell 2013; 12: 11–23. · DOI
  18. Hockemeyer J, Burbiel JC, Müller CE . Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem 2004; 69: 3308–3318. · DOI
  19. Collins LE, Galtieri DJ, Brennum LT, Sager TN, Hockemeyer J, Müller CE et al. Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX. Pharmacol Biochem Behav 2010; 94: 561–569. · DOI
  20. Belarbi K, Burnouf S, Fernandez-Gomez FJ, Laurent C, Lestavel S, Figeac M et al. Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease like Tau pathology. Neurobiol Dis 2011; 43: 486–494. · DOI · Paper page
  21. Planel E, Richter KE, Nolan CE, Finley JE, Liu L, Wen Y et al. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci 2007; 27: 3090–3097. · DOI · Paper page
  22. Fernandez-Gomez FJ, Jumeau F, Derisbourg M, Burnouf S, Tran H, Eddarkaoui S et al. Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting. J Vis Exp, advance online publication, 10 April 2014; doi:10.3791/51339. · DOI
  23. Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S et al. Detrimental effects of diet-induced obesity on tau pathology are independent of insulin resistance in tau transgenic mice. Diabetes 2013; 62: 1681–1688. · DOI
  24. Batalha VL, Pego JM, Fontinha BM, Costenla AR, Valadas JS, Baqi Y et al. Adenosine A(2A) receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. Mol Psychiatry 2013; 18: 320–331. · DOI · Paper page
  25. Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean ME et al. Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Memory 2011; 95: 296–304. · DOI
  26. Bert L, Favale D, Jego G, Greve P, Guilloux JP, Guiard BP et al. Rapid and precise method to locate microdialysis probe implantation in the rodent brain. J Neurosci Methods 2004; 140: 53–57. · DOI
  27. Sauvinet V, Parrot S, Benturquia N, Bravo-Moraton E, Renaud B, Denoroy L . In vivo simultaneous monitoring of gamma-aminobutyric acid, glutamate, and L-aspartate using brain microdialysis and capillary electrophoresis with laser-induced fluorescence detection: analytical developments and in vitro/in vivo validations. Electrophoresis 2003; 24: 3187–3196. · doi:10.1002/elps.200305565
  28. Zilka N, Kovacech B, Barath P, Kontsekova E, Novak M . The self-perpetuating tau truncation circle. Biochem Soc Trans 2012; 40: 681–686. · DOI
  29. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG . Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 2004; 165: 1643–1652. · DOI · Paper page
  30. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A et al. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflamm 2010; 7: 56. · DOI · Paper page
  31. Bardou I, Brothers HM, Kaercher RM, Hopp SC, Wenk GL . Differential effects of duration and age on the consequences of neuroinflammation in the hippocampus. Neurobiol Aging 2013; 34: 2293–2301. · DOI
  32. Rebola N, Simoes AP, Canas PM, Tome AR, Andrade GM, Barry CE et al. Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem 2011; 117: 100–111. · DOI · Paper page
  33. Matos M, Augusto E, Agostinho P, Cunha RA, Chen JF . Antagonistic interaction between adenosine A2A receptors and Na+/K+-ATPase-alpha2 controlling glutamate uptake in astrocytes. J Neurosci 2013; 33: 18492–18502. · DOI
  34. Cristovao-Ferreira S, Navarro G, Brugarolas M, Perez-Capote K, Vaz SH, Fattorini G et al. A1R-A2AR heteromers coupled to Gs and G i/0 proteins modulate GABA transport into astrocytes. Purinergic Signal 2013; 9: 433–449. · DOI
  35. Albasanz JL, Perez S, Barrachina M, Ferrer I, Martin M . Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathol 2008; 18: 211–219. · DOI · Paper page
  36. Zhou SJ, Zhu ME, Shu D, Du XP, Song XH, Wang XT et al. Preferential enhancement of working memory in mice lacking adenosine A(2A) receptors. Brain Res 2009; 1303: 74–83. · DOI
  37. Wei CJ, Singer P, Coelho J, Boison D, Feldon J, Yee BK et al. Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learn Memory 2011; 18: 459–474. · DOI
  38. Leite MR, Wilhelm EA, Jesse CR, Brandao R, Nogueira CW . Protective effect of caffeine and a selective A2A receptor antagonist on impairment of memory and oxidative stress of aged rats. Exp Gerontol 2011; 46: 309–315. · DOI
  39. Ning YL, Yang N, Chen X, Xiong RP, Zhang XZ, Li P et al. Adenosine A2A receptor deficiency alleviates blast-induced cognitive dysfunction. J Cerebr Blood Flow Metab 2013; 33: 1789–1798. · DOI
  40. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309: 476–481. · DOI · Paper page
  41. Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF . Adenosine A(2A) receptor mediates microglial process retraction. Nature Neurosci 2009; 12: 872–878. · DOI · Paper page
  42. Dai SS, Zhou YG, Li W, An JH, Li P, Yang N et al. Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci 2010; 30: 5802–5810. · DOI · Paper page
  43. Yu L, Shen HY, Coelho JE, Araujo IM, Huang QY, Day YJ et al. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 2008; 63: 338–346. · DOI · Paper page
  44. Boison D . Adenosine dysfunction in epilepsy. Glia 2012; 60: 1234–1243. · DOI · Paper page
  45. Studer FE, Fedele DE, Marowsky A, Schwerdel C, Wernli K, Vogt K et al. Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience 2006; 142: 125–137. · DOI · Paper page
  46. Shen HY, Singer P, Lytle N, Wei CJ, Lan JQ, Williams-Karnesky RL et al. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. J Clin Invest 2012; 122: 2567–2577. · DOI
  47. Yee BK, Singer P, Chen JF, Feldon J, Boison D . Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. Eur J Neurosci 2007; 26: 3237–3252. · DOI
  48. Matos M, Augusto E, Machado NJ, dos Santos-Rodrigues A, Cunha RA, Agostinho P . Astrocytic adenosine A2A receptors control the amyloid-β peptide-induced decrease of glutamate uptake. J Alzheimers Dis 2012; 31: 555–567. · DOI
  49. Cristovao-Ferreira S, Vaz SH, Ribeiro JA, Sebastiao AM . Adenosine A2A receptors enhance GABA transport into nerve terminals by restraining PKC inhibition of GAT-1. J Neurochem 2009; 109: 336–347. · DOI
  50. Xu XH, Zheng XX, Zhou Q, Li H . Inhibition of excitatory amino acid efflux contributes to protective effects of puerarin against cerebral ischemia in rats. Biomed Environ Sci 2007; 20: 336–342.
  51. Dong X, Zhang D, Zhang L, Li W, Meng X . Osthole improves synaptic plasticity in the hippocampus and cognitive function of Alzheimer’s disease rats via regulating glutamate. Neural Regen Res 2012; 7: 2325–2332.
  52. Luo J, Min S, Wei K, Li P, Dong J, Liu YF . Propofol protects against impairment of learning-memory and imbalance of hippocampal Glu/GABA induced by electroconvulsive shock in depressed rats. J Anesth 2011; 25: 657–665. · DOI
  53. Altinbilek B, Manahan-Vaughan D . Antagonism of group III metabotropic glutamate receptors results in impairment of LTD but not LTP in the hippocampal CA1 region, and prevents long-term spatial memory. Eur J Neurosci 2007; 26: 1166–1172. · DOI
  54. Dong Z, Bai Y, Wu X, Li H, Gong B, Howland JG et al. Hippocampal long-term depression mediates spatial reversal learning in the Morris water maze. Neuropharmacology 2013; 64: 65–73. · DOI · Paper page
  55. Rodrigues TM, Jeronimo-Santos A, Sebastiao AM, Diogenes MJ . Adenosine A(2A) receptors as novel upstream regulators of BDNF-mediated attenuation of hippocampal long-term depression (LTD). Neuropharmacology 2014; 79: 389–398. · DOI
  56. Min SS, Quan HY, Ma J, Han JS, Jeon BH, Seol GH . Chronic brain inflammation impairs two forms of long-term potentiation in the rat hippocampal CA1 area. Neurosci Lett 2009; 456: 20–24. · DOI
  57. Peineau S, Nicolas CS, Bortolotto ZA, Bhat RV, Ryves WJ, Harwood AJ et al. A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases. Mol Brain 2009; 2: 22. · DOI
  58. Ahmed T, Blum D, Burnouf S, Demeyer D, Buée-Scherrer V, D'Hooge R et al. Inhibition of GSK3β and activation of PP2A rescue defects in NMDAR-mediated late phase LTD in a Tau transgenic mouse model. Neurobiology of Aging, (in press).

Cited by

See all 188

Metadata

Authors
Laurent, C., Burnouf, S., Ferry, B., Batalha, V. L., Coelho, J. E., Baqi, Y., Malik, E., Mariciniak, E., Parrot, S., Van der Jeugd, A., Faivre, E., Flaten, V, Ledent, C., D'Hooge, R., Sergeant, N., Hamdane, M., Humez, S., Müller, C. E., Lopes, L. V., Buée, L., & Blum, D.
Venue
Molecular Psychiatry
Published
2014-12-02
Volume
21
Issue
1
Pages
97-107
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W1986745837
Cited by
188
References
6
FWCI
7.19
Type
journal article
Language
en
Update notices
erratum (2015-07-28)
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.